Overview

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Changchun Huayang High-tech Co., Ltd
Collaborator:
Beijing Bionovo Medicine Development Co., Ltd.